PLK1 drives cellular proliferation, is overexpressed in a wide range of tumors, and is associated with poor clinical outcomes (30–34), making this kinase an attractive candidate for targeted cancer therapeutics and prompting the clinical development of multiple PLK1 inhibitors (31). This evidence concerns the gene PLK1 and cancer.